JP2007501806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501806A5 JP2007501806A5 JP2006522842A JP2006522842A JP2007501806A5 JP 2007501806 A5 JP2007501806 A5 JP 2007501806A5 JP 2006522842 A JP2006522842 A JP 2006522842A JP 2006522842 A JP2006522842 A JP 2006522842A JP 2007501806 A5 JP2007501806 A5 JP 2007501806A5
- Authority
- JP
- Japan
- Prior art keywords
- ribavirin
- dose
- interferon
- use according
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 5
- 239000008185 minitablet Substances 0.000 claims description 3
- 238000009792 diffusion process Methods 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 29
- 229960000329 ribavirin Drugs 0.000 claims 27
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 27
- 108010050904 Interferons Proteins 0.000 claims 17
- 102000014150 Interferons Human genes 0.000 claims 17
- 229940079322 interferon Drugs 0.000 claims 17
- 230000036765 blood level Effects 0.000 claims 9
- 238000013268 sustained release Methods 0.000 claims 7
- 239000012730 sustained-release form Substances 0.000 claims 7
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 208000036142 Viral infection Diseases 0.000 claims 6
- 239000003963 antioxidant agent Substances 0.000 claims 6
- 230000003078 antioxidant effect Effects 0.000 claims 6
- 239000012528 membrane Substances 0.000 claims 6
- 230000009385 viral infection Effects 0.000 claims 6
- 230000003836 peripheral circulation Effects 0.000 claims 5
- 239000003223 protective agent Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 210000003240 portal vein Anatomy 0.000 claims 4
- 230000003442 weekly effect Effects 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000007910 systemic administration Methods 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229950000038 interferon alfa Drugs 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 2
- 239000013563 matrix tablet Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49482803P | 2003-08-13 | 2003-08-13 | |
| PCT/AU2004/001031 WO2005016370A1 (en) | 2003-08-13 | 2004-08-03 | Method of treating viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501806A JP2007501806A (ja) | 2007-02-01 |
| JP2007501806A5 true JP2007501806A5 (https=) | 2007-09-20 |
Family
ID=34193246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522842A Pending JP2007501806A (ja) | 2003-08-13 | 2004-08-03 | ウィルス感染を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070202078A1 (https=) |
| EP (1) | EP1660116A4 (https=) |
| JP (1) | JP2007501806A (https=) |
| CN (1) | CN1835765A (https=) |
| AR (1) | AR045263A1 (https=) |
| AU (1) | AU2004264255A1 (https=) |
| BR (1) | BRPI0413474A (https=) |
| CA (1) | CA2535451A1 (https=) |
| CL (1) | CL2004002030A1 (https=) |
| IL (1) | IL173630A0 (https=) |
| NO (1) | NO20060651L (https=) |
| NZ (1) | NZ545159A (https=) |
| RU (1) | RU2371195C2 (https=) |
| WO (1) | WO2005016370A1 (https=) |
| ZA (1) | ZA200601181B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| EP1492511B3 (fr) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| CN1847256B (zh) * | 2005-04-13 | 2011-06-15 | 长春华普生物技术有限公司 | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 |
| WO2006131790A2 (en) * | 2005-06-09 | 2006-12-14 | Flamel Technologies | Oral ribavirin pharmaceutical composition |
| WO2009031918A1 (ru) * | 2007-09-05 | 2009-03-12 | Shatunovsky Nikolai Evgenievic | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с |
| WO2009046369A2 (en) * | 2007-10-05 | 2009-04-09 | Medtronic, Inc. | Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| CA2737376A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| EP2459211A1 (en) | 2009-07-31 | 2012-06-06 | Medtronic, Inc. | Continuous subcutaneous administration of interferon- to hepatitis c infected patients |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| SG190357A1 (en) | 2010-11-19 | 2013-06-28 | Venus Remedies Ltd | Novel conjugates for targeted drug delivery |
| RU2665638C1 (ru) * | 2017-05-24 | 2018-09-03 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3222259A (en) * | 1963-10-25 | 1965-12-07 | Ethyl Corp | Flare stack with a liquid seal |
| JPS5439143Y2 (https=) * | 1976-04-16 | 1979-11-20 | ||
| ES2186660T3 (es) * | 1997-09-21 | 2003-05-16 | Schering Corp | Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica. |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| AU766597B2 (en) * | 1998-05-15 | 2003-10-16 | Schering Corporation | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection |
| TR200101085T2 (tr) * | 1998-10-16 | 2001-08-21 | Schering Corporation | Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| WO2000037110A2 (en) * | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
| DE59905248D1 (de) * | 1999-01-29 | 2003-05-28 | Disphar Int Bv | Pharmazeutische zusammensetzungen |
| CA2306039A1 (en) * | 1999-04-19 | 2000-10-19 | Schering Corporation | Hcv combination therapy |
| US6924270B2 (en) * | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| AU2002213343A1 (en) * | 2000-10-18 | 2002-04-29 | Schering Corporation | Ribavirin-pegylated interferon alfa HCV combination therapy |
| US6544497B2 (en) * | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| PL369129A1 (en) * | 2001-09-28 | 2005-04-18 | Intermune, Inc. | Method for treating hepatitis c virus infection in treatment failure patients |
| CA2372987A1 (en) * | 2001-12-11 | 2003-06-11 | Thomas R. Wiseman | Method of disposal of liquid from gas wells |
-
2004
- 2004-08-03 JP JP2006522842A patent/JP2007501806A/ja active Pending
- 2004-08-03 RU RU2006107566/15A patent/RU2371195C2/ru not_active IP Right Cessation
- 2004-08-03 ZA ZA200601181A patent/ZA200601181B/en unknown
- 2004-08-03 BR BRPI0413474-5A patent/BRPI0413474A/pt not_active IP Right Cessation
- 2004-08-03 NZ NZ545159A patent/NZ545159A/en unknown
- 2004-08-03 EP EP04737647A patent/EP1660116A4/en not_active Ceased
- 2004-08-03 CA CA002535451A patent/CA2535451A1/en not_active Abandoned
- 2004-08-03 AU AU2004264255A patent/AU2004264255A1/en not_active Abandoned
- 2004-08-03 US US10/568,176 patent/US20070202078A1/en not_active Abandoned
- 2004-08-03 WO PCT/AU2004/001031 patent/WO2005016370A1/en not_active Ceased
- 2004-08-03 CN CNA200480023166XA patent/CN1835765A/zh active Pending
- 2004-08-09 CL CL200402030A patent/CL2004002030A1/es unknown
- 2004-08-12 AR ARP040102894A patent/AR045263A1/es unknown
-
2006
- 2006-02-09 IL IL173630A patent/IL173630A0/en unknown
- 2006-02-09 NO NO20060651A patent/NO20060651L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI241913B (en) | Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C | |
| KR20060120037A (ko) | Ｈｃｖ 감염 치료용 병용 요법 | |
| JP2002515453A5 (https=) | ||
| SK155997A3 (en) | Use of ribavirin and interferon alpha for the treatment of hepatitis c | |
| EP1536839B1 (en) | Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus | |
| JP2007501806A5 (https=) | ||
| US20110165119A1 (en) | Telaprevir dosing regimen | |
| RU2006107566A (ru) | Способ лечения вирусных инфекций | |
| CA2563058A1 (en) | Supportive treatment of liver disease | |
| RU2002105485A (ru) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) | |
| TW200808327A (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma | |
| US20130225483A1 (en) | New Treatments of Hepatitis C Virus Infection | |
| US20150139950A1 (en) | Alisporivir to treat hepatitis c virus infection | |
| Kushner et al. | Direct-Acting Antiviral Agents | |
| MXPA06001695A (en) | Method of treating viral infections | |
| US20160235808A1 (en) | Treatment of Hepatitis C Virus Infection with Alisporivir | |
| EP2450051A1 (en) | Medicinal agent and method for treatment of intractable chronic hepatitis c | |
| NZ615539B2 (en) | Treatment of hepatitis c virus infection with alisporivir |